Table 2 |
||||
|
Association of four-marker rs9358890-rs3799344-rs1183201-rs12664474 haplotypes with gout |
||||
|
Frequency |
||||
|
|
||||
|
Haplotypea |
Case |
Control |
OR (95% CI) |
P value |
|
|
||||
|
Caucasian |
||||
|
A-T-A-A |
270 (0.339) |
1044 (0.428) |
0.66 (0.56 to 0.78) |
1.5 × 10-6 |
|
A-C-T-A |
327 (0.410) |
876 (0.360) |
1.22 (1.03 to 1.44) |
0.014 |
|
A-C-T-G |
121 (0.152) |
284 (0.117) |
1.34 (1.06 to 1.69) |
0.015 |
|
G-C-T-G |
47 (0.059) |
104 (0.043) |
1.39 (0.98 to 1.98) |
0.067 |
|
EP/N |
||||
|
A-T-A-A |
107 (0.239) |
101 (0.274) |
0.84 (0.61 to 1.15) |
0.27 |
|
A-C-T-A |
160 (0.356) |
109 (0.297) |
1.33 (0.99 to 1.78) |
0.06 |
|
G-C-T-G |
161 (0.360) |
140 (0.380) |
0.93 (0.70 to 1.23) |
0.60 |
|
EP/Z |
||||
|
A-T-A-A |
32 (0.372) |
120 (0.414) |
0.84 (0.51 to 1.38) |
0.49 |
|
A-C-T-A |
32 (0.372) |
111 (0.384) |
0.95 (0.58 to 1.56) |
0.84 |
|
G-C-T-G |
9 (0.105) |
26 (0.090) |
1.19 (0.53 to 2.64) |
0.68 |
|
A-C-T-G |
10 (0.116) |
22 (0.075) |
1.63 (0.74 to 3.59) |
0.23 |
|
WP |
||||
|
A-C-T-A |
171 (0.357) |
96 (0.343) |
1.07 (0.78 to 1.45) |
0.70 |
|
A-T-A-A |
116 (0.241) |
89 (0.318) |
0.68 (0.49 to 0.94) |
0.021 |
|
G-C-T-G |
171 (0.356) |
77 (0.275) |
1.46 (1.06 to 2.02) |
0.021 |
|
A-C-T-G |
12 (0.025) |
12 (0.043) |
0.57 (0.25 to 1.29) |
0.17 |
|
EP/WP |
||||
|
A-T-A-A |
5 (0.167) |
16 (0.400) |
0.30 (0.10 to 0.95) |
0.035 |
|
A-C-T-A |
15 (0.500) |
13 (0.324) |
2.08 (0.78 to 5.50) |
0.14 |
|
G-C-T-G |
6 (0.200) |
11 (0.275) |
0.66 (0.21 to 2.05) |
0.47 |
|
|
||||
|
CI, confidence interval; EP, Eastern Polynesian; OR, odds ratio; WP, Western Polynesian. aHaplotypes are listed in descending order of control frequency; those with frequency < 0.03 were excluded. |
||||
|
Hollis-Moffatt et al. Arthritis Research & Therapy 2012 14:R92 doi:10.1186/ar3816 |
||||
